Alprostadil

證據等級: L5

預測適應症: 10 個

Alprostadil: From Erectile Dysfunction / Peripheral Arterial Disease to Aortic Malformation

One-Sentence Summary

Alprostadil (Prostaglandin E1, PGE1) is a synthetic prostaglandin primarily approved in major markets for erectile dysfunction and peripheral arterial occlusive disease, with well-established use for maintaining patent ductus arteriosus in neonates with ductus-dependent congenital heart disease. The TxGNN model predicts it may be specifically effective for Aortic Malformation, with 2 clinical trials and 20 publications currently supporting this direction. The mechanistic basis is direct and well-characterised: aortic malformations such as interrupted aortic arch and critical aortic stenosis are paradigmatic ductus-dependent lesions for which PGE1 ductal maintenance is the cornerstone of preoperative stabilisation.

Quick Overview

Item	Content
Original Indication	Not available in Singapore regulatory records (no active registrations); globally approved for erectile dysfunction and peripheral arterial disease
Predicted New Indication	Aortic Malformation
TxGNN Prediction Score	99.98%
Evidence Level	L3
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacology, Alprostadil is the synthetic analogue of Prostaglandin E1 (PGE1), acting primarily on EP2 and EP4 receptors expressed on ductal smooth muscle cells. Receptor binding triggers intracellular cAMP upregulation, leading to smooth muscle relaxation and vasodilation. This mechanism directly reverses the postnatal oxygen-driven constriction of the ductus arteriosus, maintaining ductal patency as a haemodynamic bypass route.

Aortic malformations — including interrupted aortic arch (IAA), critical coarctation of the aorta, and aortic atresia — are structurally obstructive lesions of the left-sided cardiac outflow. In these conditions, the ductus arteriosus provides the sole pathway connecting the pulmonary artery to the descending aorta, bypassing the obstruction and sustaining systemic perfusion to the lower body, abdominal organs, and kidneys. Without a patent ductus, circulatory collapse occurs within days of birth. This makes these lesions "ductus-dependent" and PGE1 the only pharmacological agent currently available to prevent ductal closure preoperatively.

As Jonas (2015) documented in a landmark review, "the introduction of prostaglandin E1 in the late 1970s revolutionized the management of interrupted aortic arch." Multiple publications in this evidence pack consistently confirm PGE1's critical preoperative role across the spectrum of aortic malformations, from aortic atresia to critical coarctation. The TxGNN prediction therefore captures a mechanistically sound and globally well-established application that is simply absent from Singapore's regulatory record.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04054115	Phase 1	Terminated	10	Tested Alprostadil's acute effects on cerebral and pulmonary blood flow after bidirectional cavopulmonary connection (second-stage single-ventricle palliation). Preliminary findings indicate Alprostadil increases cerebral blood flow via vasodilation. Study terminated early with only 10 participants; cannot provide efficacy conclusions, but offers a mechanistic safety signal supporting vasodilatory activity in congenital cardiac contexts.
NCT02042092	N/A	Completed	39	Imaging comparison study (Colour Doppler Ultrasonography vs. MRI Angiography) in systemic large vessel vasculitis; does not test Alprostadil directly. Included as contextual vascular imaging evidence; limited direct relevance to drug repurposing evaluation for aortic malformation.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26686446	2015	Review	Semin Thorac Cardiovasc Surg	PGE1 introduction "revolutionised" interrupted aortic arch management; supports preoperative resuscitation with PGE1 before one-stage neonatal repair with direct arch anastomosis and VSD closure.
6763200	1982	Case Series	Pharmacotherapy	Direct evaluation of Alprostadil in congenital malformations including aortic lesions; demonstrates ductal dilation, improved pulmonary blood flow, and restored systemic oxygenation in ductus-dependent defects.
19080093	2008	Quasi-RCT	Zhonghua Yi Xue Za Zhi	Alprostadil (Lipo-PGE1) combined with ulinastatin attenuates inflammatory response and lung injury post-cardiopulmonary bypass in paediatric CHD patients; suggests cardioprotective mechanisms extending beyond ductal maintenance alone.
7201134	1982	Case Series	Pediatric Cardiology	PGE1 infusion in neonates with hypoplastic left ventricle and aortic atresia; transient haemodynamic improvement confirmed in 6 of 7 infants, reinforcing the role of PDA maintenance in severe left-sided aortic obstruction.
32184038	2020	Retrospective Cohort	Asian J Surg	Staged surgical repair for interrupted aortic arch in Taiwan; PGE1 infusion was integral to preoperative stabilisation at each surgical stage. Confirms the contemporary surgical paradigm of PGE1 bridge therapy.
25647388	2014	Review / Clinical Guideline	Cardiology in the Young	Preoperative management of critical neonatal aortic valvar stenosis; PGE1 recommended to maintain ductal patency and systemic perfusion prior to urgent valvotomy or catheter-based intervention.
6537955	1984	Case Series	J Am Coll Cardiol	Long-term PGE1 infusion (mean 39 days, up to 104 days) in 17 neonates including those with aortic coarctation; documents sustained ductal patency and characterises prolonged-infusion side effects including cortical hyperostosis.
1926911	1991	Review	DICP Ann Pharmacother	Recommends PGE1 stabilisation prior to neonatal transport for suspected ductus-dependent defects including aortic lesions; establishes the standard protocol for PGE1 initiation at referring hospitals before transfer.
10771966	1998	Case Series	Indian J Pediatrics	PGE1 as first-stage palliation in neonates with ductus-dependent CHD in India; includes aortic coarctation and interrupted arch; documents efficacy and safety profile in a non-Western, resource-limited clinical setting.
28508920	2017	Case Report	Pediatric Cardiology	Neonate with critical aortic coarctation developed second- and third-degree atrioventricular block during chronic low-dose PGE1 infusion; conduction disturbances resolved promptly upon discontinuation. Critical safety signal for cardiac rhythm monitoring during Alprostadil therapy.

Singapore Market Information

Alprostadil (DrugBank DB00770) is currently not registered in Singapore. No active product licences are on record with the Health Sciences Authority (HSA).

Clinical deployment in Singapore would require either a new HSA product registration or access via named-patient or compassionate-use pathways. Reference regulatory approvals exist in the United States (FDA), European Union (EMA), and Japan (PMDA), which may serve as supporting data packages for a future Singapore submission.

Safety Considerations

Please refer to the package insert for safety information.

The following safety signals are consistently documented across the clinical literature in this evidence pack and should directly inform clinical monitoring planning:

Apnoea: A dose-dependent and well-recognised side effect of PGE1 infusion in neonates; respiratory monitoring and readiness for ventilatory support are essential throughout infusion.
Gastrointestinal complications: Prolonged PGE1 infusion is associated with antral foveolar hyperplasia and hypertrophic pyloric stenosis (PMIDs 25263728, 23521358). Gastrointestinal assessment is warranted for infusions extending beyond two weeks.
Cardiac rhythm disturbances: Second- and third-degree AV block documented at low doses in a neonate with critical aortic coarctation (PMID 28508920); continuous cardiac rhythm monitoring is required.
Cortical hyperostosis of long bones: Reported with extended infusion; bone surveillance may be appropriate in prolonged use scenarios.
Fever and peripheral flushing: Common, generally self-limiting vasodilatory side effects.

Formal safety data from local regulatory sources — including package insert warnings, contraindications (data gap DG001), and complete mechanism of action documentation (data gap DG002) — remain outstanding and must be retrieved before clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Alprostadil's application in aortic malformation is mechanistically direct, biologically well-grounded, and supported by decades of consistent published evidence across case series, retrospective cohorts, and expert clinical guidelines (L3 evidence). The primary barriers to clinical use in Singapore are regulatory (no HSA registration) and safety documentation gaps — not scientific plausibility or evidence of harm. The absence of a completed Phase 3 RCT for this specific indication reflects the rarity of the neonatal population and the ethical constraints of placebo-controlled trials in critically ill newborns, not an absence of clinical confidence.

To proceed, the following is needed:

Regulatory pathway: Initiate HSA product registration or apply for named-patient/compassionate-use access; leverage existing FDA, EMA, or PMDA approvals as reference data packages.
Safety data retrieval: Obtain full prescribing information from an approved jurisdiction to resolve DG001 (formal warnings and contraindications) and DG002 (MOA confirmation); critical given the narrow therapeutic window in neonatal patients.
DDI screening: Formally assess interactions with agents routinely co-administered in neonatal cardiac intensive care, including vasopressors (dopamine, dobutamine), anticoagulants (heparin), and prostaglandin synthetase inhibitors (NSAIDs, indomethacin, which may counteract PGE1 activity).
Institutional clinical protocol: Establish guidelines for dose titration, monitoring intervals (respiratory, cardiac rhythm, gastrointestinal), maximum infusion duration, and criteria for transitioning to surgical intervention.
Prospective outcome registry: Establish a Singapore-based registry for neonates receiving Alprostadil for ductus-dependent aortic lesions to generate local real-world evidence and address the evidence gap from the absence of jurisdiction-specific controlled trial data.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.